Autoinflammatory syndromes in chronic urticaria are rare but clinically distinct: A retrospective cohort study Authors: Ethan Bendayan, Jessica SS Ho, Megha Udupa, Fatemah AlYaqout, Moshe Ben-Shoshan, Catherine Zhu, Tania Cruz Marino, Michael Fein, Elena Netchiporouk Published: 2026 To the Editor: Chronic urticaria (CU), including spontaneous and inducible forms, is a mast cell–driven disease with heterogeneous mechanisms such as type I and type IIb autoimmunity and aberrant mast cell activation.1 Although most cases follow these pathways, autoinflammatory syndromes (AIS) may occasionally present with urticaria-like eruptions, often accompanied by systemic symptoms and poor response to standard therapies.2 Understanding the frequency and spectrum of AIS in CU cohorts is important to guide recognition and appropriate work-up. We performed a retrospective analysis of the prospective CUTAN-R registry (2013-2025) at the McGill University Health Centre, a certified Urticaria Centers of Reference and Excellence center.1,3 Standard investigations followed international guidelines and included complete blood count, thyroid peroxidase IgG, total immunoglobulin E, and C-reactive protein (CRP).2 Additional testing (eg, autoantibodies, skin biopsy, serum protein electrophoresis, and genetic testing) was pursued when symptoms, findings, or initial laboratories were abnormal. AIS work-up was specifically triggered by features such as persistently or episodically elevated CRP, systemic symptoms (eg, fever and weight loss), extracutaneous inflammation (eg, arthralgia and colitis), episodic flares, atypical hives (eg, nonpruritic, lasting >24 hours, or resolving with bruising/purpura). AIS diagnoses were based on established clinical diagnostic criteria; genetic findings served as supportive evidence. Among 573 patients with CU, 36.0% were <18 years and 59.0% were female. After the phenotype-guided approach outlined in Fig 1, 16 (2.8%) patients exhibited red-flag features together with abnormal initial autoinflammatory investigations, prompting further evaluation; variants in autoinflammatory genes were identified in 14. AIS diagnosis was established in 8 (1.4%): Yao syndrome (n = 4), Schnitzler-like syndrome (n = 1), familial Mediterranean fever (FMF, n = 2), and adult-onset Still disease (n = 1) (Table I).4 All cases were refractory to guideline-based CU therapy, except 1 FMF case. For confirmed AIS cases, the median age at AIS onset was 34.5 years (IQR, 23.0-50.0), 75.0% were female, and only 1 FMF case was diagnosed during childhood, before urticaria onset. The most frequent systemic features were arthralgias (87.5%), fatigue (62.5%), recurrent fevers (50.0%), and elevated CRP (42.9%). One patient with FMF had no systemic symptoms at CU presentation, likely because of prior FMF recognition and management. Six additional patients carried variant of unknown significance in AIS-associated genes or were heterozygous for autosomal-recessive AIS genes (Table I).4 Although their contribution to disease pathogenesis is biologically plausible, current evidence is insufficient for AIS diagnosis. Stepwise, phenotype-guided approach to evaluating autoinflammatory syndromes (AIS) in patients presenting with chronic urticaria. Patients with chronic urticaria (CU) are first classified as chronic inducible urticaria (CIndU) or chronic spontaneous urticaria (CSU). Red-flag features (eg, recurrent fevers, inflammatory arthralgias, gastrointestinal or ocular inflammation, wheals lasting >24 hours, residual bruising or purpura, persistently elevated inflammatory markers, or marked refractoriness to guideline-based therapy) prompt stepwise evaluation. Initial investigations target common secondary causes (autoimmune, inflammatory, and paraproteinemic conditions), with skin biopsy when urticarial vasculitis or bullous pemphigoid is suspected. Genetic testing is reserved for patients with high clinical suspicion after exclusion of secondary causes, broad autoinflammatory gene panels including full NOD2 sequencing with intronic coverage are preferred. Targeted empirical therapy may be considered in patients with pathogenic or likely pathogenic variants, and selectively for variant of unknown significance (VUS) or heterozygous variants in autosomal recessive genes when clinical concordance is high. Figure created with BioRender. ANA, Antinuclear antibody; AR, autosomal recessive; CBC, complete blood count; CCP, cyclic citrullinated peptide; C4, complement component 4; CRP, C-reactive protein; C3, complement component 3; ENA, extractable nuclear antigen; ESR, erythrocyte sedimentation rate; IL, interleukin; IRA, increased risk allele; LFT, liver function test; LPV, likely pathogenic variant; PV, pathogenic variant; RF, rheumatoid factor; SPEP, serum protein electrophoresis; TPO, thyroid peroxidase; UAS7, Urticaria Activity Score over 7 days; UCT, Urticaria Control Test. ∗A skin biopsy can help rule out urticarial vasculitis and neutrophilic dermatoses. ∗∗IRA applies specifically to NOD2 variants in YAOS and does not follow American College of Medical Genetics and Genomics and Association for Molecular Pathology classification. †Variant reclassification may be performed using the American College of Medical Genetics and Genomics and Association for Molecular Pathology criteria.5 Table IDemographic, clinical, and red-flag features of patients in the chronic urticaria cohort investigated for autoinflammatory syndromesPtSex/ethnicityAIS status (Dx criteria)Age (y) at AIS onset/Dx or testingRed-flag features at presentationGenetic/biopsy findingsFailed TxCurrent TxTx response∗AIS diagnosis established (n = 8)1F/WhiteSchnitzler-like syndrome†52/62Fatigue; recurrent fevers; arthralgias; CRP ↑; ANA 1:160Negative genetic testing; biopsy compatible with neutrophilic urticariasgAHs; HCQ; omalizumab; colchicineAnakinraComplete2F/WhiteYAOS (Yao criteria)48/51Fatigue; arthralgias; colitis; sicca; ANA 1:160; anti-CCP IgG +; extensive treatment failureNOD2 IRA (c.2104C>T)sgAHs; HCQ; montelukast; MTX; CZP; upadacitinib; etanercept; tocilizumabsgAHs; SSZ; colchicine; adalimumabPartial3M/WhiteYAOS (Yao criteria)29/33Recurrent fevers; arthralgias; CRP ↑NOD2 IRA (c.3019dup); NFAT5 VUS (c.3552_3563del); biopsy compatible with neutrophilic urticariasgAHs; infliximabsgAHs; colchicine; adalimumabComplete4F/WhiteYAOS (Yao criteria)27/38Fatigue; arthralgiasNOD2 IRA (c.2104C>T); RMRP PV (n.71A>G); SP110 VUS (c.185C>T)sgAHs; colchicine; SSZsgAHs; anakinra; SCIG‡Complete5F/South AsianYAOS (Yao criteria)56/58Arthralgias; fatigue; chills; recurrent headaches; recurrent fevers; ANA 1:80; extensive treatment failureNOD2 IRA (c.1958A>C) [VUS]; biopsy compatible with urticariasgAHs; montelukast; cyclosporine; omalizumab; methotrexate; dupilumab; sulfasalazine; abrocitinibsgAHs; anakinraPartial6M/Middle EasternFMF (Tel-Hashomer criteria)2/2None§Not availableNonesgAHs; colchicineComplete7F/WhiteAOSD (Yamaguchi criteria)19/20Arthralgias; recurrent fevers; HLH; CRP ↑; ferritin ↑; LDH ↑; C4 ↓Biopsy compatible with early neutrophilic urticaria or urticarial vasculitissgAHssgAHs; tocilizumabComplete8F/Middle EasternFMF (Tel-Hashomer criteria)40/61Recurrent severe arthralgias myalgias, chest, and abdominal pains; fatigue; uveitis; colitis; familial clusteringHeterozygous MEFV PV (c.2080A>G)‡; DNAAF2 PV (c.1199_1214dup)sgAHs; omalizumab; dupilumabColchicineCompleteAIS diagnosis not established (n = 8)9F/Middle EasternNo diagnostic criteria met33/37Extensive treatment failureHeterozygous for AR IL10RB LPV (c.552G>A); biopsy compatible with urticariasgAHs; omalizumab; dupilumab; cyclosporine; montelukast; abrocitinibsgAHs; upadacitinibPartial10F/WhiteNo diagnostic criteria met34/38Arthritis; malaise; chills; CRP ↑Heterozygous for AR ZAP70 PV (c.1529_1532dup); biopsy compatible with urticariasgAHs; secukinumab; omalizumabsgAHs; colchicine; upadacitinib; montelukastComplete11M/Middle EasternNo diagnostic criteria met24/25Arthralgias; recurrent fever; weight loss; colitis; CRP ↑Heterozygous for AR SPINK5 PV (c.1431-12G>A); biopsy compatible with urticariasgAHs; anakinra; colchicinesgAHs; omalizumabPartial12F/WhiteNo diagnostic criteria met40/47Arthralgias; sicca; CRP ↑; serum amyloid A ↑; ANA 1:160Heterozygous for AR CYBA VUS (c.203+5>A); heterozygous for AR ITGB2 VUS (c.1754C>T); biopsy compatible with urticariasgAHs; omalizumab; cyclosporine; montelukast; colchicine; dapsone; anakinrasgAHs; omalizumab; pregabalin; cyclosporineComplete13F/WhiteNo diagnostic criteria met43/45Arthralgias; myalgias; fatigue; recurrent headaches; muscle spasms; chronic rhinitis; tinnitus; GERD; family history of CSUHeterozygous for AD IRF2BP2 VUS (c.860C>T); heterozygous for AD RAC2 VUS (c.57C>T); biopsy not performedsgAHs; colchicine; omalizumab (300 mg monthly)sgAHs; omalizumab (600 mg monthly); montelukast; famotidineComplete14F/WhiteNo diagnostic criteria met14/25Arthralgias; recurrent fevers; flushing; atypical wheals (blistering); sicca; colitis; oral ulcers; CRP ↑Heterozygous for AD NLRP12 VUS (exon 4 deletion); biopsy not performedsgAHs; prednisone; colchicine; anakinraSulfasalazinePartial15F/WhiteNo diagnostic criteria met15/31Nausea; vomiting; colitis; recurrent headaches; difficulty concentrating; fatigue; flushingNegative AIS panel; negative c-KIT; negative TPSAB1; first biopsy revealed possible JLIS or LE; second biopsy revealed possible papular urticaria or AI-CTDsgAHs; famotidine; montelukast; SCG; ketotifen; omalizumabsgAHs; dupilumabComplete16F/WhiteNo diagnostic criteria met19/38Arthralgias; colitis; sicca; brain fogNegative AIS panel; biopsy not performedsgAHs; omalizumab; adalimumabUpadacitinib, semaglutideCompleteNOD2 variants in YAOS function as susceptibility alleles in a low-penetrance, immune-modulating gene rather than after classic Mendelian inheritance; IRA terminology reflects this genetic architecture, but does not follow American College of Medical Genetics and Genomics and Association for Molecular Pathology criteria.4AD, Autosomal dominant; AI-CTD, autoimmune connective tissue disorder; AIS, autoinflammatory syndrome; ANA, antinuclear antibody; AOSD, adult-onset Still disease; AR, autosomal recessive; CCP, cyclic citrullinated protein; C4, complement component 4; CRP, C-reactive protein; CSU, chronic spontaneous urticaria; CZP, certolizumab; Dx, diagnosis; F, female; FMF, familial Mediterranean fever; GERD, gastroesophageal reflux disease; HCQ, hydroxychloroquine; Het, heterozygous; HLH, hemophagocytic lymphohistiocytosis; IRA, increased risk allele; JLIS, Jessner lymphocytic infiltration of the skin; LDH, lactate dehydrogenase; LE, lupus erythematosus; LPV, likely pathogenic variant; M, male; MTX, methotrexate; Pt, patient; PV, pathogenic variant; SCG, sodium cromoglycate; SCIG, subcutaneous immunoglobulin; sgAH, second-generation H1 antihistamine; SSZ, sulfasalazine; TPSAB1, tryptase alpha/beta 1; Tx, treatment; VUS, variant of unknown significance; YAOS, Yao syndrome.∗A complete response refers to resolution of urticaria and systemic symptoms, whereas a partial response indicates improvement of urticaria with residual systemic symptoms (or vice versa).†Although this patient does not meet formal Strasbourg criteria because of absence of monoclonal gammopathy, the presentation aligns with previously described cases of Schnitzler-like syndrome in the literature.‡FMF is usually inherited in an autosomal recessive manner, but heterozygous variants can contribute to disease in some patients.§Symptom history and laboratory values were not available before treatment initiation and disease control. Demographic, clinical, and red-flag features of patients in the chronic urticaria cohort investigated for autoinflammatory syndromes NOD2 variants in YAOS function as susceptibility alleles in a low-penetrance, immune-modulating gene rather than after classic Mendelian inheritance; IRA terminology reflects this genetic architecture, but does not follow American College of Medical Genetics and Genomics and Association for Molecular Pathology criteria.4 AD, Autosomal dominant; AI-CTD, autoimmune connective tissue disorder; AIS, autoinflammatory syndrome; ANA, antinuclear antibody; AOSD, adult-onset Still disease; AR, autosomal recessive; CCP, cyclic citrullinated protein; C4, complement component 4; CRP, C-reactive protein; CSU, chronic spontaneous urticaria; CZP, certolizumab; Dx, diagnosis; F, female; FMF, familial Mediterranean fever; GERD, gastroesophageal reflux disease; HCQ, hydroxychloroquine; Het, heterozygous; HLH, hemophagocytic lymphohistiocytosis; IRA, increased risk allele; JLIS, Jessner lymphocytic infiltration of the skin; LDH, lactate dehydrogenase; LE, lupus erythematosus; LPV, likely pathogenic variant; M, male; MTX, methotrexate; Pt, patient; PV, pathogenic variant; SCG, sodium cromoglycate; SCIG, subcutaneous immunoglobulin; sgAH, second-generation H1 antihistamine; SSZ, sulfasalazine; TPSAB1, tryptase alpha/beta 1; Tx, treatment; VUS, variant of unknown significance; YAOS, Yao syndrome. A complete response refers to resolution of urticaria and systemic symptoms, whereas a partial response indicates improvement of urticaria with residual systemic symptoms (or vice versa). Although this patient does not meet formal Strasbourg criteria because of absence of monoclonal gammopathy, the presentation aligns with previously described cases of Schnitzler-like syndrome in the literature. FMF is usually inherited in an autosomal recessive manner, but heterozygous variants can contribute to disease in some patients. Symptom history and laboratory values were not available before treatment initiation and disease control. In a Urticaria Centers of Reference and Excellence center cohort, ∼1% of patients with CU had AIS, most often Yao syndrome. This frequency reflects a phenotype-enriched tertiary referral population in which genetic testing was selectively performed, and should not be interpreted as generalizable prevalence estimate. Aside from the patient with FMF with a longstanding diagnosis, all confirmed cases initially presented as CU; subsequent identification of AIS features prompted reclassification, suggesting these represent AIS mimicking CU rather that true overlap. Clinically, red-flag features including systemic symptoms, elevated CRP, atypical eruptions, and treatment refractoriness, were present in all confirmed cases, supporting their use as pragmatic triggers for AIS evaluation in daily practice (Fig 1).4 The proposed algorithm should be viewed as an expert-informed pragmatic framework rather than a validated clinical pathway. Limitations include the single-center design, small number of AIS cases, absence of functional assays for variant of unknown significance interpretation, and potential for circular reasoning in phenotype-guided genetic testing, particularly for Yao syndrome, where variants are frequently classified as variant of unknown significance and the syndrome itself remains incompletely defined5; results may not generalize to settings with different ancestry or referral patterns. Conflicts of interest Dr Netchiporouk has been a speaker or consultant, or has received investigator-initiated research funding from AbbVie, Arcutis, Bausch Health, Boehringer Ingelheim International, Bristol Myers Squibb, Celltrion, Galderma, Janssen, LEO Pharma, Medexus, Novartis Pharmaceuticals, Pfizer, Sanofi Genzyme, Sun Pharmaceuticals, Eli Lilly, and UCB, and is the founder of the Montreal Derm FilEZ website, a nonprofit educational resource. Dr Ben-Shoshan has served as a speaker for Sanofi, Novartis, Celltrion, Pfizer, and Viatris, and as a principal investigator for studies sponsored by Novartis and Sanofi. Dr Fein has been a speaker or consultant, or has received investigator-initiated research funding from ALK, Astra-Zeneca, Bausch Health, Celltrion, CSL Behring, Medexus, Novartis, Sanofi, and Viatris, and is the founder of AllergyIQ.ca, a nonprofit educational resource. Bendayan, Ho, Udupa, AlYaqout, Zhu, and Cruz Marino have no conflicts of interest to declare. Acknowledgments The authors thank the Canadian Dermatology Foundation for making this research possible. Footnotes Drs Bendayan and Ho contributed equally to this article and are cofirst authors. Drs Fein and Netchiporouk contributed equally to this article and are cosenior authors. Funding sources: Funded by the Canadian Dermatology Foundation. IRB approval status: Approved by McGill University Health Centre (IRB #12-255 GEN). References